Onychomycosis Treatment Market, By Treatment Type (Drugs, Laser Therapy, and Photodynamic Therapy), By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Other Types), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.
Market Dynamics:
Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.
For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.
Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook